These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2390749)

  • 21. The effect of educational gifts from pharmaceutical firms on medical students' recall of company names or products.
    Sandberg WS; Carlos R; Sandberg EH; Roizen MF
    Acad Med; 1997 Oct; 72(10):916-8. PubMed ID: 9347716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Bioavailability and the assessment of bioequivalence in the control of pharmaceutical preparations].
    Ciranni Signoretti E
    Ann Ist Super Sanita; 1982; 18(3):547-50. PubMed ID: 7187843
    [No Abstract]   [Full Text] [Related]  

  • 23. [Relationship between clinical pharmacology and pharmaceutical industry].
    Ponec K
    Cas Lek Cesk; 1973 Jun; 112(26):821-8. PubMed ID: 4718381
    [No Abstract]   [Full Text] [Related]  

  • 24. WHO Expert Committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 25 years of Bayesian methods in the pharmaceutical industry: a personal, statistical bummel.
    Grieve AP
    Pharm Stat; 2007; 6(4):261-81. PubMed ID: 17955514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioavailability of drugs.
    J Ir Med Assoc; 1973 Oct; 66(19):547 passim. PubMed ID: 4759091
    [No Abstract]   [Full Text] [Related]  

  • 27. Accredited pharmaceutical manufacturers representatives.
    Bell W
    Can Med Assoc J; 1979 Jun; 120(11):1327. PubMed ID: 455177
    [No Abstract]   [Full Text] [Related]  

  • 28. [When physicians prepare drugs].
    Poulsen HS; Ulrichsen H
    Ugeskr Laeger; 2001 Oct; 163(40):5545-6. PubMed ID: 11601126
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessment of therapeutic equivalence in drug registration and control.
    Idänpään-Heikkilä J
    Ann Clin Res; 1974; 6(0):suppl 11:71-8. PubMed ID: 4850672
    [No Abstract]   [Full Text] [Related]  

  • 30. [The "third party" in the pharmaceutical industry].
    Karrer E
    Boll Chim Farm; 1966 Aug; 105(8):563-9. PubMed ID: 6003361
    [No Abstract]   [Full Text] [Related]  

  • 31. Do pharmaceutical representatives misuse their drug samples?
    Tong KL; Lien CY
    Can Fam Physician; 1995 Aug; 41():1363-6. PubMed ID: 7580385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug company 'suppressed' publication of research.
    Wadman M
    Nature; 1996 May; 381(6577):4. PubMed ID: 8609985
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pathological aspects in the pharmaceutical industry: diseases in the workers assigned to extraction and compounding of drugs].
    Nava C; Briatico-Vangosa G; Marchisio M; Arbosti G
    Med Lav; 1974; 65(3-4):118-27. PubMed ID: 4444680
    [No Abstract]   [Full Text] [Related]  

  • 34. International Conference on Harmonisation; guidance on good manufacturing practice for active pharmaceutical ingredients; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Sep; 66(186):49028-9. PubMed ID: 12358036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Computation of the threshold of profitability of a pharmaceutical production facility].
    Smecka V; Solich J
    Cesk Farm; 1979 Feb; 28(1):3-5. PubMed ID: 110468
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmaceutical applications of polymorphism.
    Haleblian J; McCrone W
    J Pharm Sci; 1969 Aug; 58(8):911-29. PubMed ID: 4899118
    [No Abstract]   [Full Text] [Related]  

  • 37. Accreditation program geared to broaden scope of pharmaceutical representatives.
    Can Hosp; 1970 Jan; 47(1):53. PubMed ID: 5434682
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug nomenclature: suggestions for change.
    Tevaarwerk JM
    CMAJ; 1993 Mar; 148(5):714-5. PubMed ID: 8439927
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug safety: the viewpoint of the pharmaceutical manufacturing industry.
    Wigle WW
    Can Med Assoc J; 1968 Feb; 98(6):314-7. PubMed ID: 5636099
    [No Abstract]   [Full Text] [Related]  

  • 40. [Drug dosage form and action].
    Zathurecký L
    Med Klin; 1974 Apr; 69(16):667-70. PubMed ID: 4837397
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.